as suspected not black and white outcome which is typical for trials data
but the key will be if TGA accepts the data for schedule 3 being granted - then it is a completely different ball game as all CND currently prescribed under Special Access Scheme for insomnia will not be able to be supplied - the Schedule 3 BOD product would be only product that can be supplied and that would be over the counter at any chemist so that would be a big outcome.
smy read is still in the game and way further down track it seems than competitors - if value of schedule 3 is X and it has been discounted significantly to date, then that discount has to change on back of these findings and stock should re-rate up to reflect lower discount to potential ,commercialisation value .....
BOD Price at posting:
6.7¢ Sentiment: Hold Disclosure: Held